TrialBritish journal of cancer2023

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.

Rebecca Kristeleit et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.